Related Experiment Video

Updated: May 4, 2026

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

1.5K

Hypoglycemic and hypolipidemic effect of Aloe vera L. in non-insulin dependent diabetics

Monika Choudhary1, Anita Kochhar1, Jaswinder Sangha1

  • 1Department of Food and Nutrition, College of Home Science, Punjab Agricultural University, Ludhiana, 141 004 India.

Journal of Food Science and Technology
|January 16, 2014
PubMed

Insights

Aloe vera L. gel powder supplementation significantly reduced blood glucose and improved lipid profiles in non-insulin dependent diabetic patients. This natural intervention also helped lower blood pressure, offering a promising approach to diabetes management.

Area of Science:

  • Endocrinology and Metabolism
  • Nutritional Science
  • Pharmacognosy

Background:

  • Type 2 diabetes mellitus (T2DM) poses a significant global health challenge.
  • Management often involves lifestyle modifications and pharmacotherapy.
  • Exploring natural adjunct therapies like Aloe vera L. is crucial for comprehensive diabetes care.

Purpose of the Study:

  • To evaluate the efficacy of Aloe vera L. gel powder supplementation in managing T2DM.
  • To assess its impact on glycemic control, lipid profiles, and blood pressure.
  • To determine optimal dosage for therapeutic benefits.

Main Methods:

  • A randomized controlled trial involving 90 T2DM subjects divided into three groups.
  • Groups II and III received 100 mg and 200 mg of Aloe vera L. gel powder, respectively, for 6 months.
  • Group I served as a control. Blood glucose, lipid profiles, and blood pressure were monitored.

Main Results:

  • Significant reductions in fasting and post-prandial blood glucose levels were observed in both Aloe vera L. supplemented groups (p≤0.01).
  • Marked improvements in lipid profiles, including decreased total cholesterol, triglycerides, LDL-C, VLDL-C, and increased HDL-C, were noted (p≤0.01).
  • Significant reductions in systolic and diastolic blood pressure were also recorded in supplemented groups (p≤0.01).

Conclusions:

  • Aloe vera L. gel powder supplementation demonstrates significant hypoglycemic and hypolipidemic effects in T2DM patients.
  • The herb also contributes to blood pressure reduction, suggesting a multifaceted therapeutic role.
  • Dosage-dependent benefits were observed, highlighting Aloe vera L. as a potential complementary therapy for diabetes management.

Keywords:
Aloe vera L.Blood glucoseBlood pressureLipid profileNutrition counselling

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K
An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993